SCHEMBL1468935

SCHEMBL1468935

COCCOc1cnc2[nH]cc(NC(=O)C3CC3)c2c1N1CCCC(NC(=O)OC(C)(C)C)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 4/20 0.41
JAK3 P52333 2/20 0.41
MAP4K4 O95819 2/20 0.39
AURKA O14965 3/20 0.37
PDPK1 O15530 3/20 0.37
AURKB Q96GD4 3/20 0.37
PDE10A Q9Y233 1/20 0.36
EGFR P00533 1/20 0.36
LCK P06239 1/20 0.36
RET P07949 1/20 0.36
ROCK1 Q13464 2/20 0.35
CDC42BPB Q9Y5S2 2/20 0.35
ROCK2 O75116 1/20 0.35
CDK9 P50750 1/20 0.35
KIF18A Q8NI77 1/20 0.35
AAK1 Q2M2I8 2/20 0.35
SYK P43405 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
STK17B O94768 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1468938 1.00 BTK (0.41) BTKJAK3MAP4K4AURKAPDPK1
SCHEMBL1469362 0.92 BTK (0.44) BTKJAK3MAP4K4AURKAPDPK1
SCHEMBL1469361 0.92 BTK (0.44) BTKJAK3MAP4K4AURKAPDPK1
SCHEMBL1468325 0.90 ROCK1 (0.37) BTKJAK3LCKROCK1CDC42BPB
SCHEMBL1468672 0.86 BTK (0.48) BTKJAK3MAP4K4AURKAPDPK1
SCHEMBL1468671 0.86 BTK (0.48) BTKJAK3MAP4K4AURKAPDPK1
SCHEMBL1468674 0.86 BTK (0.44) BTKJAK3MAP4K4AURKAPDPK1
SCHEMBL1468673 0.86 BTK (0.44) BTKJAK3MAP4K4AURKAPDPK1
SCHEMBL1468986 0.84 AAK1 (0.39) ROCK1CDC42BPBROCK2AAK1STK17B
SCHEMBL1468984 0.84 AAK1 (0.39) ROCK1CDC42BPBROCK2AAK1STK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9969727-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-05-15 US disclosed
US-20160368916-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-12-22 US disclosed
US-9365568-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2016-06-14 US disclosed
EP-2990407-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-03-02 EP disclosed
US-20150322061-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-11-12 US disclosed
EP-2307409-B1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-08-12 EP disclosed
US-8981085-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-03-17 US disclosed
US-20140243520-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-08-28 US disclosed
US-8758830-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-06-24 US disclosed
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-04-10 US disclosed
US-8545897-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-10-01 US disclosed
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2013-02-21 US disclosed
US-8178131-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-05-15 US disclosed
EP-2307409-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2011-04-13 EP disclosed
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-03-24 US disclosed
WO-2009140320-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243520-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A BTK 1141/4885JAK3 1577/4885MAP4K4 135/4885
US-20160368916-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A BTK 1141/4885JAK3 1577/4885MAP4K4 135/4885
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A BTK 1141/4885JAK3 1577/4885MAP4K4 135/4885
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, BUB1B BTK 919/4885JAK3 1382/4885MAP4K4 115/4885
US-20150322061-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A BTK 1141/4885JAK3 1577/4885MAP4K4 135/4885
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A BTK 1141/4885JAK3 1577/4885MAP4K4 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.